Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Tempus AI — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $25.54 (market cap $142.30B), while Tempus AI trades at $58.5 (market cap $10.54B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 13.5× Tempus AI's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.2% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| BBVA | TEM | |
|---|---|---|
Market Cap | $142.30B | $10.54B |
Sector | Financials | Broad Market / Factor |
52-Week High | $26.14 | $103.25 |
52-Week Low | $14.73 | $42.37 |
Dividend Yield | 4.2% | — |
Enterprise Value | — | $11.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $25.39, down 1.17% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 26.51% net income margin and 18.67% ROE. Recent earnings beat expectations in Q1 2026, and revenue has grown steadily from $28.2B in 2022 to $39.4B in 2025. Positive analyst sentiment is reflected in a 53.85% buy rating, though legal and regulatory risks from ongoing probes in Spain present headwinds.
The outlook for BBVA remains positive given robust profitability and analyst support, but investors should weigh the stock's attractive valuation against litigation risks and sector volatility. Upside potential exists if earnings continue to exceed forecasts, but legal developments could pressure the share price near-term.
Tempus AI (TEM) trades at $55.93, down 3.95% on the day, with strong analyst support (61.5% buy ratings) and a $69.20 consensus price target. The stock shows bullish technical signals with support at $55 and resistance at $58, while fundamentals reveal robust revenue growth ($1.27B in 2025) but significant losses (-$245M net income). Recent news highlights the company's expanding AI healthcare data platform and FDA approvals driving investor optimism despite ongoing profitability challenges.
TEM presents a high-risk, high-reward opportunity with Wall Street bullish on its unique healthcare data moat and AI capabilities. The primary investment thesis centers on the company's positioning to dominate precision medicine, though shareholders face substantial execution risk amid persistent losses and negative cash flow from operations. Near-term catalysts include Q2 2026 earnings on July 30 and continued expansion of high-margin data services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
